Leuprolide vs Triptorelin — Peptide Comparison

Leuprolide vs Triptorelin — Peptide Comparison Leuprolide vs Triptorelin — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Leuprolide 3.75 mg–45 mg monthly or 3-month injections (depending on formulation) Triptorelin 0.1 mg–22.5 mg mg Frequency Once daily Administration Subcutaneous injection (daily) Intramuscular injection Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Cancer Management Endometriosis & Fibroid Relief Hormone Control Hormone Regulation Endometriosis Relief Technical Data Molecular Formula C59H84N16O12 Molecular Weight 1209.4 g/mol Half-Life Approximately 2-6 hours (varies by route of administration) Bioavailability ~95% (subcutaneous injection) CAS Number 74381-53-6 C64H82N18O13 1311.4 g/mol 2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations) ~100% (intramuscular/subcutaneous injection) 57773-63-4 Protocols standard 1 mg Ongoing The original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4]. starting 7.5 mg Every month The 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5]. 22.5 mg Every 3 months The 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5]. advanced 30-45 mg Every 4-6 months The longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5]. 3.75 mg Once every 4 weeks Ongoing while indicated FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5]. 11.25 mg Once every 12 weeks FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5]. Once every 24 weeks FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6]. Applications Managing advanced or metastatic prostate cancer Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Controlling severe endometriosis pain Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treating symptomatic uterine fibroids Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Delaying early puberty in children Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing advanced prostate cancer when combined with other treatments Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Relieving severe endometriosis pain and symptoms Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Delaying puberty development in children with early sexual maturation Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Hot flashes (very common in men) Decreased libido and erectile dysfunction Injection site pain or swelling Nausea Fatigue Mood changes or depression Joint or muscle pain Headaches Dizziness Thinning hair Decreased bone density (osteoporosis with long-term use) QT prolongation (rare but serious cardiac effect) Tumor flare (temporary worsening of cancer symptoms in first weeks) Severe allergic reactions Spinal cord compression risk in men with metastatic disease Serious Severe allergic reaction Research Status FDA Status FDA approved for this use Safety Overview Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. Contraindications xPregnancy or breastfeeding (teratogenic) xUndiagnosed vaginal bleeding xActive bone metastases with spinal cord compression (increased fracture risk) xAllergy to GnRH agonists or components xSevere cardiovascular disease with QT prolongation risk Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months. xPregnancy (can affect fetal development) xKnown hypersensitivity to GnRH agonists xSevere untreated depression xActive spinal cord compression in prostate cancer (requires urgent decompression) Decision Guide Choose Leuprolide if... Managing advanced or metastatic prostate cancer Controlling severe endometriosis pain Treating symptomatic uterine fibroids Delaying early puberty in children Choose Triptorelin if... Managing advanced prostate cancer when combined with other treatments Relieving severe endometriosis pain and symptoms Delaying puberty development in children with early sexual maturation